How Pfizer’s COVID Vaccine Spent The Weekend After Its EUA
Executive Summary
Our infographic shows the journey from Kalamazoo to an arm near you.
You may also be interested in...
NIH Considering Trial of COVID-19 Vaccines and Asymptomatic Transmission
US FDA’s Peter Marks says transmission prevention is one of three key missing data points he’d like from Pfizer and BioNTech’s newly authorized vaccine. Another concern is how the vaccine will work is the virus “drifts.”
Pink Sheet Podcast: Regeneron’s COVID Monoclonal Deal, New FDA Advisor, Project Optimus In Cancer Combos
Pink Sheet reporter and editors discuss the somewhat novel pricing language in Regeneron’s deal with the US government to develop a COVID-19 monoclonal antibody, US FDA Commissioner Robert Califf hiring a new senior advisor, and optimizing dosing in cancer combination therapies.
Litigation Against Medicare Price Negotiation Gains Four Potential New Plaintiffs
Abbvie, Amgen, Novartis and Novo Nordisk have drugs on the list but haven’t sued yet. While they could add to the ranks of legal opposition, the Court Battle for the IRA is more about philosophy than numbers.